News

Neutral Dr Reddy`s Laboratories Ltd For Target Rs.1,390 By Motilal Oswal Financial Services Ltd North America/Russia/ROW drive earnings Limited visibility to grow beyond the g-Revlimid opportunity * Dr Reddy’s Lab (DRRD) delivered in-line 2QFY25 performance. DRRD exhibited robust YoY growth in North America (NA), Russia, and ROW markets and a healthy scale-up in the pharmaceutical services and active ingredients segment. This was offset by moderate YoY growth in the Europe/CIS business. * Higher volume growth and new launches have been the key factors driving su...
Neutral Dr Reddy`s Laboratories Ltd For Target Rs.1,390 By Motilal Oswal Financial Services Ltd
Neutral Dr Reddy`s Laboratories Ltd For Target Rs.1,390 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
2024-11-19 02:50:29 pm
Dr. Reddy's Laboratories declines on the BSE Dr. Reddy's Laboratories is currently trading at Rs. 1188.85, down by 37.20 points or 3.03% from its previous closing of Rs. 1226.05 on the BSE. The scrip opened at Rs. 1195.60 and has touched a high and low of Rs. 1221.00 and Rs. 1171.00 respectively. So far 40061 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1420.20 on 21-Aug-2024 and a 52 week low of Rs. 1074.35 on 11-Dec-2023. Last one week high and lo...
Dr. Reddy's Laboratories declines on the BSE
Dr. Reddy's Laboratories declines on the BSE
Source: Accord Fintech
2024-11-18 11:15:49 am
Hold Dr. Reddy`s Laboratories Ltd For Target Rs. 1,449 By Choice Broking Ltd Dr. Reddy’s quarterly earnings were above our expectations on the revenue front but lower on earnings. On the revenue front, DRRD reported the highest-ever quarterly revenue of INR 80,382mn, with a robust YoY growth of 16.5% and 4.4% QoQ, the increase was mainly driven by growth in the global generic business. EBITDA reported at INR 20,765mn (+3.4% YoY and -2.5%QoQ) and the margin saw a decline of 326bps YoY and 184bps QoQ to 25.8% on account of change in the mix and one-time acquisitio...
Hold Dr. Reddy`s Laboratories Ltd For Target Rs. 1,449 By Choice Broking Ltd
Hold Dr. Reddy`s Laboratories Ltd For Target Rs. 1,449 By Choice Broking Ltd
Source: Choice Broking
2024-11-13 11:28:56 am
Buy Dr Reddys Laboratories Ltd For Target Rs.1,655 By JM Financial Services New initiatives to help avoid Revlimid cliff DRRD delivered a strong performance with Revenue/EBITDA/PAT growing 17%/11%/-8% YoY ahead of JMFe and street expectations. US business (8% beat) was led by gRevlimid ramp-up, albeit softer QoQ, was the primary driver. Complex launches and biosimilars will sustain momentum in this business over the medium term. NRT acquisition will reflect from 3Q further improving core margins. India business (in line) improvement was visible with around 9-10% e...
Buy Dr Reddys Laboratories Ltd For Target Rs.1,655 By JM Financial Services
Buy Dr Reddys Laboratories Ltd For Target Rs.1,655 By JM Financial Services
Source: JM Financial Services Ltd
2024-11-07 02:58:20 pm
Dr. Reddy`s Laboratories jumps despite reporting 9% fall in Q2 consolidated net profit Dr. Reddy's Laboratories is currently trading at Rs. 1300.55, up by 28.00 points or 2.20% from its previous closing of Rs. 1272.55 on the BSE. The scrip opened at Rs. 1272.25 and has touched a high and low of Rs. 1322.00 and Rs. 1251.50 respectively. So far 110555 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1420.20 on 21-Aug-2024 and a 52 week low of Rs. 1,064.52 on 06-Nov-2023. Last one week high and lo...
Dr. Reddy`s Laboratories jumps despite reporting 9% fall in Q2 consolidated net profit
Dr. Reddy`s Laboratories jumps despite reporting 9% fall in Q2 consolidated net profit
Source: Accord Fintech
2024-11-06 02:58:29 pm
Dr Reddy's Laboratories Ltd. Q2FY25 Result First Cut – Revenue gains momentum; Net profit drops due to weak US demand - The Company reported revenue growth of 16.5% YoY and 4.4% QoQ to Rs. 8,038 crores, above market expectations of Rs. 7,717 crores. - The Global Generics (GG) segment witnessed broad based revenue growth of 17.0% YoY / up 4.0% QoQ to Rs. 7,158 crores, driven by improved sales volumes and new product launches. Emerging Markets and Europe primarily drove sequential growth. - EBITDA increased 3.4% YoY / down 2.5% QoQ to Rs. 2,077 crores, while EBITDA margin stood at 25.8% (down 326bps YoY / do...
Dr Reddy's Laboratories Ltd. Q2FY25 Result First Cut – Revenue gains momentum; Net profit drops due to weak US demand
Dr Reddy's Laboratories Ltd. Q2FY25 Result First Cut – Revenue gains momentum; Net profit drops due to weak US demand
Source: PR Agency
2024-11-05 05:56:35 pm
India's Dr Reddy's misses Q2 profit view on weak pricing in North America Indian generic drugmaker Dr Reddy's Laboratories reported a second-quarter profit that missed analysts' expectations on Tuesday, weighed down by pricing pressure in a competitive North American market, their biggest by revenue. The company reported a 9.5% fall in its consolidated net profit after tax to 13.42 billion rupees ($159.6 million) for the quarter ended Sept. 30, missing analysts' estimate of 14.01 billion rupees, as per data compiled by LSEG. The drugmaker's to...
India's Dr Reddy's misses Q2 profit view on weak pricing in North America
India's Dr Reddy's misses Q2 profit view on weak pricing in North America
Source: Reuters
2024-11-05 05:10:47 pm
Stock of the day : Dr. Reddy's Laboratories Ltd For Target Rs. 236 - Religare Broking Dr. Reddy's Laboratories Ltd * Technical indicators visualize weaker setup in the pharma space, where DRREDDY reflects the same weakness. * Stock has recently closed below its support and important moving average (100EMA). * It has also faced multiple resistance at 50% Fibonacci retracement of its primary corrective trend. * In continuation of the breakdown from the rising trend line, bias remains negative. * Traders are recommended to comply with the trend in the mentioned...
Stock of the day : Dr. Reddy's Laboratories Ltd For Target Rs. 236 - Religare Broking
Stock of the day : Dr. Reddy's Laboratories Ltd For Target Rs. 236 - Religare Broking
Source: Religare Broking
2024-10-28 10:59:54 am
Dr. Reddy`s Laboratories rises as its arm incorporates new wholly-owned subsidiary Dr. Reddy's Laboratories is currently trading at Rs. 6704.20, up by 68.70 points or 1.04% from its previous closing of Rs. 6635.50 on the BSE. The scrip opened at Rs. 6670.00 and has touched a high and low of Rs. 6708.50 and Rs. 6640.00 respectively. So far 1375 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 7101.00 on 21-Aug-2024 and a 52 week low of Rs. 5212.10 on 30-Oct-2023. Last one week high and low o...
Dr. Reddy`s Laboratories rises as its arm incorporates new wholly-owned subsidiary
Dr. Reddy`s Laboratories rises as its arm incorporates new wholly-owned subsidiary
Source: Accord Fintech
2024-10-07 09:52:01 am
Dr. Reddy`s inches up on signing voluntary licensing agreement with Gilead Sciences Dr. Reddy's Laboratories is currently trading at Rs. 6766.80, up by 19.85 points or 0.29% from its previous closing of Rs. 6746.95 on the BSE. The scrip opened at Rs. 6745.05 and has touched a high and low of Rs. 6768.45 and Rs. 6690.00 respectively. So far 1769 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 7101.00 on 21-Aug-2024 and a 52 week low of Rs. 5212.10 on 30-Oct-2023. Last one week high and low o...
Dr. Reddy`s inches up on signing voluntary licensing agreement with Gilead Sciences
Dr. Reddy`s inches up on signing voluntary licensing agreement with Gilead Sciences
Source: Accord Fintech
2024-10-03 10:35:12 am
Saksoft, HDFC Life and Tata Motors to see some action today Saksoft has acquired Ceptes Software, a recognized expert in Salesforce services, headquartered in Bengaluru, Karnataka. The company anticipates the transaction will be closed within 4 weeks pending customary closing conditions. This strategic acquisition will significantly help Saksoft expand its capabilities around Salesforce solutions, cloud innovation, and customer experience optimization.  HDFC Life Insurance Company has received approval to raise funds up to Rs 1,500 c...
Saksoft, HDFC Life and Tata Motors to see some action today
Saksoft, HDFC Life and Tata Motors to see some action today
Source: Accord Fintech
2024-09-30 08:57:05 am
India's Zydus Lifesciences Q1 profit beats estimates on strong US demand Indian drugmaker Zydus Lifesciences reported a bigger-than-expected first-quarter profit on Friday, driven by strong demand for its generic respiratory drugs in its key market of North America. The company's consolidated net profit jumped nearly 31% year-on-year to 14.2 billion rupees ($169.2 million) in the quarter ended June 30, beat analysts' average estimate of 12.34 billion rupees, per LSEG data. KEY CONTEXT Indian generic drugmakers earn a major chunk of their revenue f...
India's Zydus Lifesciences Q1 profit beats estimates on strong US demand
India's Zydus Lifesciences Q1 profit beats estimates on strong US demand
Source: Reuters
2024-08-09 01:47:48 pm
Neutral Dr Reddy’s Labs Ltd For Target Rs.7,100 By Motilal Oswal Financial Services Strong US business offset by muted Russia/CIS  Efforts underway to scale-up JVs/integrated acquisition  * Dr. Reddy’s Lab (DRRD) delivered better-than-expected 1QFY25 earnings, led by increased traction in the US generics segment. DRRD witnessed price erosion in the US generics, EU, and ROW markets, while it experienced an increase in prices in the Russia/CIS markets. Certain investments in newer businesses and higher freight costs hit profitability to some extent.  ...
Neutral Dr Reddy’s Labs Ltd For Target Rs.7,100 By Motilal Oswal Financial Services
Neutral Dr Reddy’s Labs Ltd For Target Rs.7,100 By Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
2024-08-03 05:06:15 pm
Buy Dr Reddys Laboratories Ltd For Target Rs.8,010 By JM Financial Services Dr Reddy's reported strong performance, with both topline and EBITDA exceeding our expectations by 5 to 6%. In 1QFY25, Revenue/EBITDA/PAT grew 14%/4%/-1% YoY respectively, driven largely by ramp-up of gRevlimid. Despite higher revenue in the US (USD 463 million, +19% YoY), the EBITDA margin of 27.6% was slightly below expectations due to a significant increase in SG&A expenses – this was led by a sharp rise in freight costs. In other segments, India posted a 15% growth, aided by...
Buy Dr Reddys Laboratories Ltd For Target Rs.8,010 By JM Financial Services
Buy Dr Reddys Laboratories Ltd For Target Rs.8,010 By JM Financial Services
Source: JM Financial Services
2024-08-02 10:13:34 am
Adani Logistics, SBI among industrial partners for Telangana Skill University Adani Logistics, O9 Solutions, Dr Reddy’s Labs, State Bank of India (SBI), National Academy of Construction (NAC), Retailers Association of India, and Telangana VFX, Animation and Gaming Association will be the industry partners for Telangana's Skill University, the state Assembly was informed on Thursday.   The Assembly passed the Young India Skill University Telangana (Public-Private Partnership) Bill, 2024, setting the stage for setting up of the institution which will eq...
Adani Logistics, SBI among industrial partners for Telangana Skill University
Adani Logistics, SBI among industrial partners for Telangana Skill University
Source: IANS
2024-08-02 09:42:24 am
Dr Reddy's posts 1 pc drop in net profit at Rs 1,392 crore in Q1, revenue up 14 pc Dr Reddy's Laboratories on Saturday posted Rs 1,392 crore in net profit for the April-June quarter (year-on-year), down 1 per cent from Rs 1,402.5 crore in the same period in last fiscal.  The company clocked a 14 per cent rise in revenue in Q1 FY25 at Rs 7,672 crore, from Rs 6,738 crore in the same quarter last fiscal. “We had a good start to the new fiscal year and our growth and profitability was mainly driven by our generics business,” said GV Prasad, Co-Chairma...
Dr Reddy's posts 1 pc drop in net profit at Rs 1,392 crore in Q1, revenue up 14 pc
Dr Reddy's posts 1 pc drop in net profit at Rs 1,392 crore in Q1, revenue up 14 pc
Source: IANS
2024-07-27 05:55:04 pm
Stock Picks : Dr. Reddy`s Laboratories Ltd And Axis Bank Ltd By ICICI Direct Dr. Reddy's Laboratories Ltd Buy Dr. Reddy's Laboratories Ltd @ 6590-6596 Target 6659.00 Stop Loss 6557.00   Axis Bank Ltd. Buy Axis Bank Ltd @ 1287-1290 Target 1275.00 Stop Loss 1297.00   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : Dr. Reddy`s Laboratories Ltd And Axis Bank Ltd By ICICI Direct
Stock Picks : Dr. Reddy`s Laboratories Ltd And Axis Bank Ltd By ICICI Direct
Source: ICICI Direct
2024-07-22 11:04:39 am
Dr. Reddy's Laboratories rises on entering into patent licensing agreement with Takeda Pharmaceutical Dr. Reddy's Laboratories is currently trading at Rs. 6680.00, up by 14.90 points or 0.22% from its previous closing of Rs. 6665.10 on the BSE. The scrip opened at Rs. 6714.55 and has touched a high and low of Rs. 6714.55 and Rs. 6635.00 respectively. So far 737 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 6882.70 on 15-Jul-2024 and a 52 week low of Rs. 5,212.10 on 30-Oct-2023. Last one week high and low o...
Dr. Reddy's Laboratories rises on entering into patent licensing agreement with Takeda Pharmaceutical
Dr. Reddy's Laboratories rises on entering into patent licensing agreement with Takeda Pharmaceutical
Source: Accord Fintech
2024-07-19 10:34:34 am
Buy Dr Reddys Laboratories Ltd For Target Rs.7,390 By JM Financial Services A lucrative acquisition In line with its strategic intent, DRRD acquired Haleon’s global Nicotine Replacement Therapy (‘NRT’) OTC brands for GBP 500mn (2.3x sales) of which GBP 42mn is contingent consideration payable in CY25/26. This acquisition will help leverage customer relationships and give an opportunity to cross-sell. The management guided for better growth by reinvesting excess margins (beyond 25%). While the current growth trajectory is modest (mid-to-high singl...
Buy Dr Reddys Laboratories Ltd For Target Rs.7,390 By JM Financial Services
Buy Dr Reddys Laboratories Ltd For Target Rs.7,390 By JM Financial Services
Source: JM Financial Services
2024-07-11 12:53:07 pm
UK's Haleon to sell nicotine replacement therapy biz outside US to Dr Reddy's for $632 mn UK-based consumer healthcare company Haleon on Wednesday announced that it has entered into an agreement to sell its nicotine replacement therapy (NRT) business outside of the US to Dr Reddy's Laboratories SA for 500 million pounds (about $632.55 million).   This portfolio consists of brands including Nicotinell, Nicabate, Habitrol and Thrive available in gum, lozenge, and patch forms across over 30 markets, the company said. "The divestment of Haleon’s NRT business ...
UK's Haleon to sell nicotine replacement therapy biz outside US to Dr Reddy's for $632 mn
UK's Haleon to sell nicotine replacement therapy biz outside US to Dr Reddy's for $632 mn
Source: IANS
2024-06-27 10:04:58 am
REDUCE Dr Reddys`Ltd. For Target Rs. 5,950 - Yes Securities Performance of ex-Revlimid US business key Result Synopsis Revlimid may have just ebbed QoQ on account of some degree of weak seasonality in Q4 even as ex-Revlimid US business posted a decline due to likely timing issues in supplies. Revlimid would continue to cast a long shadow on US business as we reckon FY24 contribution could be in the ballpark of US$500mn vs ~US$300mn in the PY (our estimate). Domestic business declined on reported basis but excluding the divested brands, managemen...
REDUCE Dr Reddys`Ltd. For Target Rs. 5,950 - Yes Securities
REDUCE Dr Reddys`Ltd. For Target Rs. 5,950 - Yes Securities
Source: Yes Securities Ltd.
2024-06-24 03:05:44 pm
Accumulate Dr Reddy`s Laboratories for Target Rs 6,981 by Elara Capitals In-line Q4; relatively attractive now Q4FY24 as expected Dr Reddy`s Laboratories (DRRD IN) reported Q4FY24 revenue and EBITDA broadly in line with our estimates. PAT came in 23% ahead, helped by lower depreciation and tax and higher other income. Per our analysis, lower gRevlimid contribution was compensated for by higher base business revenue in the US and sharply higher margin in PSAI. gRevlimid – Contribution lower; US base remains strong gRevlimid, while continuing to be...
Accumulate Dr Reddy`s Laboratories for Target Rs 6,981 by Elara Capitals
Accumulate Dr Reddy`s Laboratories for Target Rs 6,981 by Elara Capitals
Source: Elara Capital
2024-06-04 04:54:53 pm
Dr. Reddy`s Laboratories moves up as its Aurigene inaugurates biologics facility in Hyderabad Dr. Reddy's Laboratories is currently trading at Rs. 5810.25, up by 26.40 points or 0.76% from its previous closing of Rs. 5783.85 on the BSE. The scrip opened at Rs. 5800.05 and has touched a high and low of Rs. 5827.95 and Rs. 5712.05 respectively. So far 3370 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 6505.50 on 28-Feb-2024 and a 52 week low of Rs. 4570.05 on 06-Jun-2023. Last one week high and low o...
Dr. Reddy`s Laboratories moves up as its Aurigene inaugurates biologics facility in Hyderabad
Dr. Reddy`s Laboratories moves up as its Aurigene inaugurates biologics facility in Hyderabad
Source: Accord Fintech
2024-06-04 10:50:41 am
Dr. Reddy`s Laboratories rises as its step down arm inks distribution agreement with Novartis Pharma Dr. Reddy's Laboratories is currently trading at Rs. 5955.85, up by 71.50 points or 1.22% from its previous closing of Rs. 5884.35 on the BSE. The scrip opened at Rs. 5884.35 and has touched a high and low of Rs. 5994.45 and Rs. 5875.90 respectively. So far 3064 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 6505.50 on 28-Feb-2024 and a 52 week low of Rs. 4483.10 on 31-May-2023. Last one week high and low o...
Dr. Reddy`s Laboratories rises as its step down arm inks distribution agreement with Novartis Pharma
Dr. Reddy`s Laboratories rises as its step down arm inks distribution agreement with Novartis Pharma
Source: Accord Fintech
2024-05-28 10:31:48 am
Neutral Dr Reddy`s Labs Ltd For Target Rs.6,070 - Motilal Oswal Financial Services US/India drive earnings growth Efforts underway to address regulatory concerns of BLA-Rituximab * Dr. Reddy’s Lab (DRRD) delivered 4QFY24 revenue in line with our estimate. However, EBITDA was lower than expected due to higher SGA expenses and R&D spending. In addition to US generics/branded generics segments, DRRD is enhancing its offering through JVs/partnerships/acquisitions in nutraceuticals, vaccine, women’s health and dietary supplement space. * We maintain our...
Neutral Dr Reddy`s Labs Ltd For Target Rs.6,070 - Motilal Oswal Financial Services
Neutral Dr Reddy`s Labs Ltd For Target Rs.6,070 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
2024-05-20 10:00:34 am
India's Dr Reddy's beats Q4 profit view; names new CFO India's generic drugmaker Dr Reddy's Laboratories reported fourth-quarter profit above expectations on Tuesday on higher U.S. and Europe sales, and appointed its new chief financial officer. M V Narasimham, who is currently the deputy CFO, will take over the role from Parag Agarwal, who held the post since 2020 and will retire on July 31. The company reported a consolidated net profit after tax of 13.10 billion rupees ($156.9 million) for the quarter ended March 31, up 36.5% fro...
India's Dr Reddy's beats Q4 profit view; names new CFO
India's Dr Reddy's beats Q4 profit view; names new CFO
Source: Reuters
2024-05-07 05:04:08 pm
Neutral Dr Reddy’s Labs Ltd For Target Rs. 5,540 - Motilal Oswal Financial Services NA/PSAI drive earnings Higher working capital needs reduce free cash flow for the quarter * Dr. Reddy’s Labs (DRRD) delivered a marginally better-than-expected performance for the quarter, led by healthy traction in the North America (NA) and Pharmaceutical Services & Active Ingredients (PSAI) segments. The India business has been witnessing moderation in YoY growth for three quarters now. DRRD continues to invest on its product pipeline, and marketing initiatives across key ...
Neutral Dr Reddy’s Labs Ltd For Target Rs. 5,540 - Motilal Oswal Financial Services
Neutral Dr Reddy’s Labs Ltd For Target Rs. 5,540 - Motilal Oswal Financial Services
Source: motilal oswal financial services Ltd
2024-04-30 11:20:12 am
Reduce Dr Reddys’ Ltd For Target Rs.1,808 - Yes Securities Result Synopsis Dr Reddys’ continues to benefit from Revlimid, potentially better traction in acquired Mayne Pharma portfolio amidst a backdrop of benign pricing environment in US. Management continues to hunt for assets as well as increase R&D (absolute + % of sales) to make use of Revlimid cash. Biosimilar monetization remains far out, beginning FY27 to make up for the likely loss of Revlimid sales in FY25 and FY26 compared to run rate in current fiscal. Domestic business is ex...
Reduce Dr Reddys’ Ltd For Target Rs.1,808 - Yes Securities
Reduce Dr Reddys’ Ltd For Target Rs.1,808 - Yes Securities
Source: Yes Securities Ltd.
2024-04-27 02:22:00 pm
Nestle India profit beats estimates on strong demand; forms JV with Dr. Reddy's Nestle India reported a bigger-than-expected increase in its quarterly profit on Thursday, as it benefited from higher product prices and demand for its packaged food items including Maggi instant noodles and KitKat chocolates. Consumer goods makers have seen steady demand for certain food items such as chocolates and biscuits, especially in urban areas, while they have also raised prices on some products including coffee and noodles to protect their bottomline. The Indian arm of the Sw...
Nestle India profit beats estimates on strong demand; forms JV with Dr. Reddy's
Nestle India profit beats estimates on strong demand; forms JV with Dr. Reddy's
Source: Reuters
2024-04-25 02:04:56 pm
IIM Raipur Celebrates 13th Annual Convocation Ceremony, Marking a Milestone in Academic Excellence The Indian Institute of Management (IIM) Raipur proudly hosted its 13th Annual Convocation Ceremony on Wednesday, April 10th, 2024, commemorating the academic achievements and successes of its graduating students. The ceremony, held at the institute's campus in Naya Raipur, was a momentous occasion filled with pride and celebration. Family members, friends, and distinguished guests were audience to 22 student exchange graduates, 298 PostGraduate Program graduates, 184E-PGP graduates, and ...
IIM Raipur Celebrates 13th Annual Convocation Ceremony, Marking a Milestone in Academic Excellence
IIM Raipur Celebrates 13th Annual Convocation Ceremony, Marking a Milestone in Academic Excellence
Source: PR Agency
2024-04-12 10:55:18 am
Buy Dr Reddys Laboratories Ltd. For Target Rs.6,585 By JM Financial Services DRRD’s US business has sustained its strong momentum led by gRevlimid, ramp-up in base business and Mayne portfolio. On an elevated FY24 base, we expect DRRD to grow its US business in single digits over the next 2 years. A part of this will be driven by higher gRevlimid volumes and new launches, in our view. We acknowledge that 25+ meaningful launches over FY25-27 may not entirely offset gRevlimid cliff but it will drive healthy ex-Revlimid earnings. India business growth has remained ...
Buy Dr Reddys Laboratories Ltd. For Target Rs.6,585 By JM Financial Services
Buy Dr Reddys Laboratories Ltd. For Target Rs.6,585 By JM Financial Services
Source: JM Financial Services
2024-04-03 01:47:03 pm
Dr. Reddy`s Laboratories rises on entering into exclusive partnership with Sanofi Healthcare India Dr. Reddy's Laboratories is currently trading at Rs. 6135.95, up by 88.35 points or 1.46% from its previous closing of Rs. 6047.60 on the BSE. The scrip opened at Rs. 6096.35 and has touched a high and low of Rs. 6185.00 and Rs. 6081.75 respectively. So far 4744 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 6505.50 on 28-Feb-2024 and a 52 week low of Rs. 4383.40 on 19-May-2023. Last one week high and low o...
Dr. Reddy`s Laboratories rises on entering into exclusive partnership with Sanofi Healthcare India
Dr. Reddy`s Laboratories rises on entering into exclusive partnership with Sanofi Healthcare India
Source: Accord Fintech
2024-03-28 11:01:10 am
Stock of the day : Dr. Reddy's Laboratories Ltd For Target Rs. 130 - Religare Broking Dr. Reddy's Laboratories Ltd * DRREDDY has been in a steady uptrend from last more than 3 months and currently price oscillating near record high levels. * It witnessed a renewed buying interest after registering a breakout from multi month corrective phase. * Following price action and bullish positioning of the momentum indicator suggests price to resume its prior trend. * We thus recommend creating longs through the Call option. BUY 6400 CE??????? Dr. Reddy'...
Stock of the day : Dr. Reddy's Laboratories Ltd For Target Rs. 130 - Religare Broking
Stock of the day : Dr. Reddy's Laboratories Ltd For Target Rs. 130 - Religare Broking
Source: Religare Broking Ltd
2024-03-19 10:46:20 am
Stock Picks : Dr. Reddy's Laboratories Ltd And DLF Ltd By ICICI Direct Dr. Reddy's Laboratories Ltd Buy Dr. Reddy's Laboratories Ltd @ 6378-6382; Target 6442.00; Stop Loss 6344.00   DLF Ltd Sell DLF Ltd @ 915-917; Target 906.00; Stop Loss 924.00   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631  
Stock Picks : Dr. Reddy's Laboratories Ltd And DLF Ltd By ICICI Direct
Stock Picks : Dr. Reddy's Laboratories Ltd And DLF Ltd By ICICI Direct
Source: ICICI Direct
2024-03-12 10:07:34 am
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says U.S. drugmaker Eli Lilly expects to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year after it clears an ongoing regulatory review, CEO David Ricks told Reuters on Wednesday. The market opportunity is huge in the world's most populous country, which has high obesity rates, especially among women, and the second-highest number of people with type-2 diabetes globally. Indian drugmakers are making their own versions of such...
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says
Source: Reuters
2024-02-28 05:09:26 pm
India pharma companies develop versions of Wegovy to get in on weight-loss windfall  Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions. ...
India pharma companies develop versions of Wegovy to get in on weight-loss windfall
India pharma companies develop versions of Wegovy to get in on weight-loss windfall
Source: Reuters
2024-02-22 12:03:24 pm
Add DR. Reddy’s laboratories Ltd For Target Rs. 763 - Choice Broking Dr. Reddy’s quarterly earnings were in-line with our expectations. Healthy performance on the revenue front (at INR 72,368mn), up 4.8% QoQ and 6.6% YoY was driven by generics business in US and Europe with contribution from both base business and new product launches. EBITDA reported at INR 20,231mn (+4.4% YoY and flattish sequentially) and margin reduced by 59bps YoY and 114bps QoQ to 28% on account of investment in sales and marketing activities, digitalization capabilities and new bu...
Add DR. Reddy’s laboratories Ltd For Target Rs. 763 - Choice Broking
Add DR. Reddy’s laboratories Ltd For Target Rs. 763 - Choice Broking
Source: Choice Broking
2024-02-21 11:43:13 am
Novartis India shares jump more than 6% after parent company announces strategic review Novartis India shares jumped more than 6 per cent on Monday after the parent company, Novartis AG announced a strategic review of its Indian arm. Novartis India was trading at Rs 1,100, up 6.23 per cent on BSE. Earlier in the day it hit a 52 week high. According to reports Dr Reddy's is likely in a race to acquire Novartis AG's stake. Dr Reddy’s said: “In this regard, please note that the company does not comment on market speculations and there is currently no such ...
Novartis India shares jump more than 6% after parent company announces strategic review
Novartis India shares jump more than 6% after parent company announces strategic review
Source: IANS
2024-02-19 03:30:58 pm
Dr. Reddy`s trades higher on the BSE Dr. Reddy's Laboratories is currently trading at Rs. 6259.85, up by 107.40 points or 1.75% from its previous closing of Rs. 6152.45 on the BSE. The scrip opened at Rs. 6200.05 and has touched a high and low of Rs. 6332.15 and Rs. 6200.05 respectively. So far 9004 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 6,332.15 on 12-Feb-2024 and a 52 week low of Rs. 4298.40 on 01-Mar-2023. Last one week high and low...
Dr. Reddy`s trades higher on the BSE
Dr. Reddy`s trades higher on the BSE
Source: Accord Fintech
2024-02-12 12:06:16 pm
India`s Zydus Lifesciences beats Q3 profit estimates; approves shares buyback Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit on Friday, driven by strong sales in its domestic and overseas markets. Consolidated net profit for the company rose 27% to 7.90 billion rupees (about $95 million) for the three months ended Dec. 31, beating analysts' average estimate of 6.83 billion rupees, as per LSEG data. Separately, Zydus Lifesciences approved the buyback of shares worth six billion rupees via tender offer r...
India`s Zydus Lifesciences beats Q3 profit estimates; approves shares buyback
India`s Zydus Lifesciences beats Q3 profit estimates; approves shares buyback
Source: Reuters
2024-02-09 02:38:55 pm
Indian drugmaker J B Chemicals posts Q3 profit rise on strong demand  India's J B Chemicals and Pharmaceuticals reported its sixth straight quarter of profit rise on Tuesday, led by strong demand in its domestic and international markets. The company's consolidated net profit was 1.34 billion rupees (nearly $16 million) for the quarter ended Dec. 31, compared with 1.06 billion rupees a year earlier. The Mumbai-based company's sales have benefitted from a series of acquisitions involving companies with portfolios of cardiovascular and oph...
Indian drugmaker J B Chemicals posts Q3 profit rise on strong demand
Indian drugmaker J B Chemicals posts Q3 profit rise on strong demand
Source: Reuters
2024-02-06 05:14:44 pm
India`s Alembic Pharma beats Q3 profit view on strong domestic, US sales India's Alembic Pharmaceuticals reported a bigger-than-expected third-quarter profit on Monday, driven by higher sales in the domestic and U.S. markets. The generic drugmaker reported a consolidated net profit of 1.80 billion rupees (nearly $22 million) for the three months ending Dec. 31, beating analysts' average estimate of 1.46 billion rupees, as per LSEG data. It had reported a profit of 1.22 billion rupees in the year-ago period. New product launches and easing price erosi...
India`s Alembic Pharma beats Q3 profit view on strong domestic, US sales
India`s Alembic Pharma beats Q3 profit view on strong domestic, US sales
Source: Reuters
2024-02-05 03:25:26 pm
India`s Torrent Pharma posts higher Q3 profit on strong domestic demand Indian drugmaker Torrent Pharmaceuticals reported a 30% rise in its pre-tax profit for the third-quarter on Friday, buoyed by robust domestic demand. Consolidated profit before exceptional items and tax grew to 5.43 billion rupees ($65.5 million) for the quarter ended Dec. 31 from 4.19 billion rupees a year earlier. Torrent, which makes drugs for diabetes, pain management, cancer and infections, logged a one-time gain of 880 million rupees during the period from the sale of a U.S. facil...
India`s Torrent Pharma posts higher Q3 profit on strong domestic demand
India`s Torrent Pharma posts higher Q3 profit on strong domestic demand
Source: Reuters
2024-02-02 03:52:53 pm
Dr Reddy`s posts 10.6% rise in Q3 net profit at Rs 1,379 cr  Pharma major Dr Reddy’s Laboratories on Tuesday reported a net profit of Rs 1,378.9 crore for the October-December quarter of the current financial year, representing a 10.6 per cent increase over the corresponding figures of Rs 1,237.90 crore for the same quarter of the previous fiscal. The company recorded its highest-ever sales in a quarter during the period, according to the management. The revenue of the Hyderabad-based company rose 6.6 per cent to Rs 7,237 crore on the...
Dr Reddy`s posts 10.6% rise in Q3 net profit at Rs 1,379 cr
Dr Reddy`s posts 10.6% rise in Q3 net profit at Rs 1,379 cr
Source: IANS
2024-01-31 11:08:10 am
For 2024, StoxBox suggests Cipla, Dr. Reddy`s.Torrent Pharma & Alkem Lab The US generics market and branded markets have seen significant growth, with moderate raw material costs and new medicines. Domestic pharmaceutical businesses are expected to grow in CY24 due to new product releases, volume growth, and increasing demand for generics and branded pharmaceuticals. Promising stocks Cipla & Dr. Reddy's US-focused pharma companies such as Sun Pharma, Lupin, and Dr. Reddy's are our preferred picks as they witnessed normalcy in demand, new launches...
For 2024, StoxBox suggests Cipla, Dr. Reddy`s.Torrent Pharma & Alkem Lab
For 2024, StoxBox suggests Cipla, Dr. Reddy`s.Torrent Pharma & Alkem Lab
Source: PR Agency
2024-01-11 12:09:40 pm
Dr. Reddy`s Laboratories rises as its arm acquires 6.46% stake Edity Therapeutics Dr. Reddy's Laboratories is currently trading at Rs. 5828.15, up by 30.25 points or 0.52% from its previous closing of Rs. 5797.90 on the BSE. The scrip opened at Rs. 5818.95 and has touched a high and low of Rs. 5853.85 and Rs. 5811.85 respectively. So far 2598 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5986.20 on 24-Aug-2023 and a 52 week low of Rs. 4176.85 on 25-Jan-2023. Last one week high and low o...
Dr. Reddy`s Laboratories rises as its arm acquires 6.46% stake Edity Therapeutics
Dr. Reddy`s Laboratories rises as its arm acquires 6.46% stake Edity Therapeutics
Source: Accord Fintech
2024-01-01 10:31:27 am
Stock of the day : Dr. Reddy`s Laboratories Ltd For Target Rs. 350 - Religare Broking Dr. Reddy's Laboratories Ltd * Pharma index trading at record highs and DRREDDY is expected to witness a catch up move. * It has recorded a breakout from bullish cup and handle pattern with noticeable volumes. * Following price action and Buoyancy in pharma space suggests bullish tone to continue and reclaim its previous swing high. * We thus recommend creating longs through the Call option. BUY 5800 CE Dr. Reddy's Laboratories Ltd CMP 240.05; Range 2...
Stock of the day : Dr. Reddy`s Laboratories Ltd For Target Rs. 350 - Religare Broking
Stock of the day : Dr. Reddy`s Laboratories Ltd For Target Rs. 350 - Religare Broking
Source: Religare Broking Ltd
2023-12-29 10:47:02 am
India`s Dr. Reddy`s shares fall on observations from US drug regulator Shares of Indian drugmaker Dr. Reddy's Laboratories were down 5.8% on Monday after the U.S. Food and Drug Administration issued three observations for the company's plant in Telangana state. The stock's decline is its steepest since mid-August, the only other time this year that it has fallen over 6%. Dr. Reddy's is also the top loser on the Nifty Pharma index, which is down 1.1%. Since touching a three-month low following its second-quarter results in late October, t...
India`s Dr. Reddy`s shares fall on observations from US drug regulator
India`s Dr. Reddy`s shares fall on observations from US drug regulator
Source: Reuters
2023-12-11 10:15:06 am